Quarterly report [Sections 13 or 15(d)]

REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)

v3.25.1
REVENUES FROM CONTRACTS WITH CUSTOMERS (Tables)
3 Months Ended
Mar. 31, 2025
REVENUES FROM CONTRACTS WITH CUSTOMERS  
Schedule of disaggregation of net revenues

Three-Month Periods Ended March 31, 

($ in thousands)

    

2025

    

2024

EmrosiTM

$

2,070

$

Qbrexza®

5,161

5,017

Accutane®

 

3,655

 

5,819

Amzeeq®

1,100

755

Zilxi®

426

273

Other / legacy

727

1,166

Total product revenues

$

13,139

$

13,030